SLS net incomeQ2 2026-$9.61M
SLS net income was -$9.61M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.60M a year earlier. For the full fiscal 2025 it was -$26.86M, compared with -$30.88M in fiscal 2024.
SELLAS Life Sciences Group Inc. (SLS) financials
For the twelve months ended Jun 30, 2026, SELLAS Life Sciences Group Inc. reported -$32.46M of net income.
- Net income, TTM
- -$32.46M
- Cash
- $138.34M
- Market cap
- $1.70B
FY2019FY2023
FY2016FY2025
SLS revenue and earnings growth
SLS EPSQ2 2026-$0.05
SLS diluted EPS was -$0.05 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.25.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $1.00M | $7.60M | $1.90M | $0 | - | - | - |
| Cost of revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | - | - | - | - |
| Gross profit | - | - | $0 | $900.0K | $7.40M | $1.90M | - | - | - | - |
| Research and development | $16.02M | $19.10M | $24.01M | $20.27M | $15.67M | $9.28M | $7.29M | $8.77M | $6.07M | $11.39M |
| Selling, general and admin | $12.25M | $12.42M | $13.86M | $12.58M | $11.32M | $9.60M | $9.92M | $12.77M | $15.09M | $4.59M |
| Operating income | -$28.27M | -$31.51M | -$37.87M | -$41.95M | -$25.29M | -$16.98M | -$20.04M | - | -$23.04M | -$15.99M |
| Pre-tax income | -$26.86M | -$30.88M | -$37.34M | -$41.30M | -$20.94M | -$16.77M | -$19.37M | -$29.05M | -$23.50M | -$17.68M |
| Income tax | $0 | $0 | $0 | $0 | -$237.0K | -$17.0K | -$81.0K | -$1.38M | $253.0K | $1.0K |
| Net income | -$26.86M | -$30.88M | -$37.34M | -$41.30M | -$20.70M | -$16.76M | -$19.29M | -$27.67M | -$23.75M | -$17.68M |
| EPS, basic | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | -$2.11 | -$10.92 | -$157.72 | -$522.00 | -$933.00 |
| EPS, diluted | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | -$2.11 | -$10.92 | -$157.72 | -$522.00 | -$933.00 |
| Diluted shares | 109.1M | 61.2M | 27.8M | 19.4M | 15.5M | 8.0M | 2.6M | 261,542 | 46,807.36 | 18,948.02 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $71.79M | $13.99M | $2.63M | $17.23M | $21.45M | $35.40M | $7.38M | $5.45M | $12.75M | $6.05M |
| Receivables | - | - | - | - | $0 | - | - | - | - | - |
| Current assets | $75.21M | $16.33M | $3.17M | $17.76M | $23.04M | $36.92M | $8.24M | $5.84M | $13.09M | $6.38M |
| Goodwill | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $5.90M |
| Total assets | $78.34M | $19.43M | $6.22M | $20.94M | $26.27M | $46.05M | $16.61M | $16.91M | $33.53M | $6.42M |
| Current liabilities | $7.02M | $9.51M | $13.73M | $15.52M | $4.98M | $12.34M | $5.29M | $5.97M | $24.57M | $5.76M |
| Short-term debt | - | - | - | - | - | - | - | $0 | $8.38M | $16.40M |
| Long-term debt | - | - | - | - | - | - | - | $0 | $2.61M | - |
| Total debt | - | - | - | - | - | - | - | $0 | $10.99M | - |
| Total liabilities | $7.47M | $9.97M | $14.20M | $16.09M | $5.93M | $18.09M | $10.52M | $11.67M | $31.46M | $11.42M |
| Shareholders' equity | $70.87M | $9.46M | -$7.98M | $4.85M | $20.35M | $27.96M | $6.09M | $5.25M | $2.07M | -$5.00M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.39M | -$35.40M | -$31.41M | -$23.81M | -$26.02M | -$10.42M | -$17.64M | -$30.42M | -$10.99M | -$11.85M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | $6.0K |
| Free cash flow | - | - | - | - | - | - | - | - | - | -$11.86M |
| Investing cash flow | - | $0 | -$5.50M | -$4.50M | $0 | - | - | $0 | $12.16M | -$85.0K |
| Financing cash flow | $86.30M | $46.76M | $22.32M | $24.08M | $12.07M | $38.44M | $19.57M | $23.12M | $5.53M | $16.50M |
| Dividends paid | - | - | - | - | - | - | $0 | $487.0K | $0 | - |
| Stock-based compensation | $1.96M | $1.56M | $2.09M | $1.73M | $1.01M | $578.0K | $573.0K | $395.0K | $3.17M | $354.0K |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | $3.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -100.0% | -86.8% | 300.0% | - | - | - | - | - |
| Gross margin | - | - | - | 90.0% | 97.4% | 100.0% | - | - | - | - |
| Operating margin | - | - | - | -4195.0% | -332.8% | -893.8% | - | - | - | - |
| Net margin | - | - | - | -4130.1% | -272.4% | -881.9% | - | - | - | - |
| Return on equity | -37.9% | -326.3% | - | -851.4% | -101.7% | -59.9% | -316.6% | -527.6% | -1147.5% | - |
| Return on assets | -34.3% | -158.9% | -600.4% | -197.2% | -78.8% | -36.4% | -116.2% | -163.6% | -70.9% | -275.4% |
| Current ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 | 2.99 | 1.56 | 0.98 | 0.53 | 1.11 |
| Debt to equity | - | - | - | - | - | - | - | 0.00 | 5.31 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Research and development | $6.27M | $5.13M | $4.73M | $4.22M | $3.87M | $3.21M | $4.44M | $4.36M | $5.19M | $5.11M | $5.10M | $5.81M |
| Selling, general and admin | $4.36M | $4.12M | $3.52M | $2.87M | $3.00M | $2.86M | $2.48M | $2.97M | $2.44M | $4.53M | $3.08M | $3.55M |
| Operating income | -$10.63M | -$9.25M | -$8.26M | -$7.08M | -$6.87M | -$6.06M | -$6.92M | -$7.33M | -$7.62M | -$9.64M | -$8.18M | -$9.36M |
| Net income | -$9.61M | -$8.41M | -$7.66M | -$6.79M | -$6.60M | -$5.81M | -$6.74M | -$7.11M | -$7.47M | -$9.57M | -$8.14M | -$9.27M |
| EPS, basic | -$0.05 | -$0.05 | - | -$0.06 | -$0.07 | -$0.07 | - | -$0.10 | -$0.13 | -$0.21 | - | -$0.33 |
| EPS, diluted | -$0.05 | -$0.05 | - | -$0.06 | -$0.07 | -$0.07 | - | -$0.10 | -$0.13 | -$0.21 | - | -$0.33 |
| Diluted shares | 189.2M | 172.5M | - | 108.4M | 98.6M | 87.8M | - | 68.3M | 57.6M | 44.8M | - | 28.4M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $138.34M | $107.10M | $71.79M | $44.32M | $25.40M | $28.50M | $13.99M | $21.13M | $9.25M | $18.52M | $2.63M | $4.07M |
| Current assets | $142.50M | $111.17M | $75.21M | $49.05M | $29.45M | $31.97M | $16.33M | $24.04M | $12.30M | $21.50M | $3.17M | $5.20M |
| Goodwill | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M |
| Total assets | $145.38M | $114.18M | $78.34M | $51.55M | $32.30M | $34.96M | $19.43M | $26.50M | $15.12M | $24.43M | $6.22M | $8.09M |
| Current liabilities | $7.57M | $6.46M | $7.02M | $5.92M | $6.00M | $6.89M | $9.51M | $10.61M | $12.04M | $14.44M | $13.73M | $11.73M |
| Total liabilities | $7.73M | $6.76M | $7.47M | $5.92M | $6.16M | $7.20M | $9.97M | $10.61M | $12.21M | $14.75M | $14.20M | $11.91M |
| Shareholders' equity | $137.66M | $107.41M | $70.87M | $45.63M | $26.15M | $27.76M | $9.46M | $15.89M | $2.91M | $9.68M | -$7.98M | -$3.83M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.59M | -$8.85M | -$4.92M | -$7.07M | -$7.33M | -$9.07M | -$7.15M | -$7.81M | -$9.68M | -$10.76M | -$4.83M | -$6.89M |
| Investing cash flow | - | - | - | - | - | - | $0 | $0 | - | - | $0 | -$3.00M |
| Financing cash flow | $38.83M | $44.15M | $32.39M | $26.09M | $4.23M | $23.58M | $8.0K | $19.69M | $414.0K | $26.65M | $3.39M | $54.0K |
| Stock-based compensation | $1.01M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 18.83 | 17.22 | 10.72 | 8.28 | 4.91 | 4.64 | 1.72 | 2.26 | 1.02 | 1.49 | 0.23 | 0.44 |
Source: XBRL data SELLAS Life Sciences Group Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Mar 15, 2017; 1-for-50, first reported Nov 14, 2019.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
SLS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SLS | - | - | -$32.46M | - | $1.70B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
SLS FAQ
4 questionsIs SLS profitable?
No. SELLAS Life Sciences Group Inc. reported a net loss of $32.46M for the twelve months ended Jun 30, 2026.How much cash and debt does SLS have?
SELLAS Life Sciences Group Inc. reported $138.34M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did SLS last report financial results?
The latest statements here come from SELLAS Life Sciences Group Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this SLS financial data come from?
Quantisnow builds these statements from the structured XBRL data SELLAS Life Sciences Group Inc. files with the SEC. It is provided for information only and is not investment advice.